Magyar K, Haberle D
Department of Pharmacodynamics, Semmelweis University of Medicine, Budapest, Hungary.
Neurobiology (Bp). 1999;7(2):175-90.
The effect of selegiline [(-)-deprenyl] cannot be considered as a simple, selective inhibitor of MAO-B. Pretreatment with the drug prevented the effect of specific neurotoxins like MPTP, 6-OH-dopamine, DSP-4 and AF64A. Selegiline pretreatment prevented the depletion of noradrenaline (NA) induced by DSP-4 in the rat hippocampus. This can be due to the uptake inhibitory effect of selegiline and mainly to its metabolite methylamphetamine (MA), which is more potent inhibitor of the re-uptake than the parent compound. SKF-525A pretreatment diminished the protective effect of selegiline against DSP-4, while phenobarbital pretreatment decreased its MAO-B inhibitory potency. Selegiline in low oral doses also prevented the effect of DSP-4 due to its intensive "first pass" metabolism. Selegiline treatment can rescue damaged neurones. It inhibited the apoptosis in M-1 human melanoma cells in a rather low concentration (10(-13)M). The mode of action of the drug regarding the inhibition of apoptosis is not known.
司来吉兰[(-)-丙炔苯丙胺]的作用不能被视为单胺氧化酶B(MAO-B)的简单、选择性抑制剂。用该药物进行预处理可防止特定神经毒素如1-甲基-4-苯基-1,2,3,6-四氢吡啶(MPTP)、6-羟基多巴胺、双硫仑(DSP-4)和AF64A的作用。司来吉兰预处理可防止DSP-4诱导的大鼠海马中去甲肾上腺素(NA)的耗竭。这可能归因于司来吉兰的摄取抑制作用,主要是其代谢产物甲基苯丙胺(MA),它是比母体化合物更强效的再摄取抑制剂。SKF-525A预处理减弱了司来吉兰对DSP-4的保护作用,而苯巴比妥预处理降低了其MAO-B抑制效力。低口服剂量的司来吉兰因其强烈的“首过”代谢也可防止DSP-4的作用。司来吉兰治疗可挽救受损神经元。它在相当低的浓度(10(-13)M)下抑制M-1人黑色素瘤细胞中的细胞凋亡。关于该药物抑制细胞凋亡的作用模式尚不清楚。